natgillin/translations-raw huggingface dataset:
Intravenously: up to 375 micrograms/square metre body surface area Intramuscularly: up to 500 micrograms/square metre body surface area
Intravensko: do 375 mikrogramov/kvadratni meter telesne površine Intramuskularno: do 500 mikrogramov/kvadratni meter telesne površine
A dose of 10 mg ketamine/kg used concurrently with 40 micrograms dexmedetomidine/ kg may cause tachycardia.
Uporaba odmerka 10 mg ketamina/kg skupaj s 40 mikrogrami deksmedetomidina/kg lahko povzroči tahikardijo.
Methyl parahydroxybenzoate (E 218)
Metilparahidroksibenzoat (E 218)
For higher weight ranges, use DEXDOMITOR 0.5 mg/ml and its dosing tables.
Za večje razpone telesne teže uporabite zdravilo DEXDOMITOR 0,5 mg/ml in pripradajoče odmerne tabele.
CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 10 ml, 10 x 10 ml
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ODMERKOV 10 ml, 10 x 10 ml
CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES 15 ml, 10 x 15 ml
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ODMERKOV 15 ml, 10 x 15 ml
After a 40 micrograms/kg bw intramuscular dose the Cmax is 17 nanograms/ml.
Po odmerku 40 mikrogramov/kg telesne teže je najvišja koncentracija (Cmax) 17 nanogramov/ml.
Premedication with dexmedetomidine will significantly reduce the dosage of the induction agent required and will reduce volatile anaesthetic requirements for maintenance anaesthesia.
Priprava na kirurški poseg z deksmedetomidinom bistveno zmanjša odmerke sredstva za indukcijo in hlapnega anestetika za vzdrževanje anestezije.
Propyl parahydroxybenzoate (E 216)
Propilparahidroksibenzoat (E 216)
Intravenously: up to 375 micrograms/square metre body surface area
Intravensko: do 375 mikrogramov/kvadratni meter telesne površine
The expected sedative and analgesic effects are reached within 15 minutes after administration and are maintained up to 60 minutes after administration.
Pričakovani sedativni in analgetični učinki se pojavijo v 15 minutah po uporabi.
MARKETING AUTHORISATION NUMBER(S) EU/2/02/033/003-004
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/02/033/003-004
MARKETING AUTHORISATION NUMBER(S) EU/2/02/033/001-002
ŠTEVILKA(E) DOVOLJENJ(A) ZA PROMET EU/2/02/033/001-002
Anaesthesia can be induced 10 minutes after premedication by intramuscular administration of a target dose of 5 mg ketamine/kg bw or by intravenous administration of propofol to effect.
10 minut po pripravi na operacijo lahko začnete anestezijo z intramuskularnim odmerkom 5 mg ketamina/kg telesne teže ali z intravenskim odmerkom propofola, dokler ni dosežen učinek.
When dexmedetomidine and butorphanol are used concomitantly in dogs bradypnoea, tachypnoea, an irregular respiratory pattern (20-30 sec apnoea followed by several rapid breaths), hypoxaemia, muscle twitch or tremor or paddling, excitation, hypersalivation, retching, vomiting, urination, skin erythema, a sudden arousal, or prolonged sedation may occur.
Pri sočasni uporabi deksmedetomidina in butorfanola se pri psih lahko pojavijo upočasnjeno ali pospešeno dihanje, nepravilni dihalni vzorci (20-30 sekund apneje, ki jim sledi nekaj hitrih vdihov), hipoksemija, trzanje mišic ali drhtenje ali brcanje, razdraženje, povečano izločanje sline, bljuvanje, bruhanje, uriniranje, kožni eritem, nenadno prebujanje ali dolgotrajna sedacija.
The dose volume of atipamezole at the concentration of 5 mg/ml is one fifth (1/5) of the dose volume of Dexdomitor 0.1 mg/ml that was given to the dog, regardless of route of administration of Dexdomitor.
Volumen odmerka atipamezola pri koncentraciji 5 mg/ml je ena petina (1/5) volumna odmerka Dexdomitorja 0,1 mg/ml, ki je bil dan psu, ne glede na način uporabe Dexdomitorja.
QUANTITY OF THE ACTIVE SUBSTANCE(S) 0.5 mg/ml dexmedetomidine hydrochloride
KOLIČINA ZDRAVILNE(IH) UČINKOVIN(E) 0,5 mg/ml deksmedetomidinijevega klorida
The safety of dexmedetomidine has not been established during pregnancy and lactation in the target species.
Pri ciljnih vrstah ni dokazana varnost deksmedetomidina v obdobju brejosti in laktacije.
After a 40 micrograms/kg bw intramuscular dose the Cmax is 17 ng/ml.
Po odmerku 40 mikrogramov/kg telesne teže je najvišja koncentracija (Cmax) 17 ng/ml.
In cats, corneal opacities may occur during sedation.
Med sedacijo lahko pride do motnosti roženice pri mačkah.
6.5 Nature and composition of immediate packaging Cardboard box with 1 glass (Type I) vial of 10ml with a chlorobutyl or bromobutyl rubber stopper and aluminium cap.
Kartonska škatla z eno 10-mililitrsko vialo iz stekla tipa I z gumijastim zamaškom iz klorobutilne ali bromobutilne gume in aluminijasto zaporko.
Any unused product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.
Vsako neporabljeno zdravilo ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z nacionalnimi zahtevami.
Intramuscular dosing at 40 mcg/kg (followed by ketamine or propofol) frequently resulted in sinus bradycardia and sinus arrhythmia, occasionally resulted in 1st degree atrioventricular block, and rarely resulted in supraventricular premature depolarizations, atrial bigeminy, sinus pauses, 2nd degree atrioventricular block, or escape beats/rhythms.
Intramuskularno dajanje v odmerku 40 mcg/kg (ki mu sledi ketamin ali propofol) je pogosto imelo za posledice sinusno bradikardijo in sinusno aritmijo, občasno izraženo v prvi stopnji atrioventrikularnega bloka ter redko supraventrikularno prezgodnjo depolarizacijo, atrijsko bigemijo, sinusni premor, drugo stopnjo atrioventrikularnega bloka ali manjkajoč utrip/ritem.
NAME OF THE VETERINARY MEDICINAL PRODUCT DEXDOMITOR 0.5 mg/ml solution for injection
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI DEXDOMITOR 0,5 mg/ml raztopina za injiciranje
Dexmedetomidine 125 micrograms/m2
Deksmedetomidín 125 mikrogramov/m2
Intramuscular dosing at 40 micrograms/kg (followed by ketamine or propofol) frequently resulted in sinus bradycardia and sinus arrhythmia, occasionally resulted in 1st degree atrioventricular block, and rarely resulted in supraventricular premature depolarizations, atrial bigeminy, sinus pauses, 2nd degree atrioventricular block, or escape beats/rhythms.
Intramuskularno dajanje v odmerku 40 mikrogramov/kg (ki mu sledi ketamin ali propofol) je pogosto imelo za posledice sinusno bradikardijo in sinusno aritmijo, občasno izraženo v prvi stopnji atrioventrikularnega bloka ter redko supraventrikularno prezgodnjo depolarizacijo, atrijsko bigemijo, sinusni premor, drugo stopnjo atrioventrikularnega bloka ali manjkajoč utrip/ritem.
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements
Vsako neporabljeno zdravilo za uporabo v veterinarski medicini ali odpadne snovi, ki nastanejo iz teh zdravil, je treba odstraniti v skladu z nacionalnimi zahtevami.
QUANTITY OF THE ACTIVE SUBSTANCE(S) 0.1 mg/ml dexmedetomidine hydrochloride
KOLIČINA ZDRAVILNE(IH) UČINKOVIN(E) 0,1 mg/ml deksmedetomidinijevega klorida
NAME OF THE VETERINARY MEDICINAL PRODUCT DEXDOMITOR 0.1 mg/ml solution for injection
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI DEXDOMITOR 0,1 mg/ml raztopina za injiciranje
The dose volume of atipamezole at the concentration of 5 mg/ml equals the dose volume of Dexdomitor that was given to the dog, regardless of route of administration of Dexdomitor.
Volumen odmerka atipamezola pri koncentraciji 5 mg/ml ustreza volumnu odmerka Dexdomitorja, ki je bil dan psu, ne glede na način uporabe Dexdomitorja.
The dose volume of atipamezole at the concentration of 5 mg/ml equals one tenth (1/10) the volume of Dexdomitor 0.1 mg/ml that was given to the cat.
Volumen odmerka atipamezola v koncentraciji 5 mg/ml je enak eni desetini (1/10) volumna odmerka Dexdomitorja 0,1 mg/ml, ki je bil dan mački.
Dexmedetomidine 375 micrograms/m2
Deksmedetomidín 375 mikrogramov/m2
The safety of dexmedetomidine has not been established in males intended for breeding.
Pri ciljnih vrstah ni dokazana varnost deksemedetomidina v obdobju brejosti in laktacije.
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE Veterinary medicinal product subject to prescription.
B POGOJI DOVOLJENJA ZA PROMET Z ZDRAVILOM TER OMEJITVE GLEDE OSKRBE IN UPORABE
One ml contains 0.1 mg dexmedetomidine hydrochloride equivalent to 0.08 mg dexmedetomidine.
1 ml vsebuje 0,1 mg deksmedetomidinijevega klorida, ki ustreza 0,08 mg deksmedetomidina
Dexmedetomidine 500 micrograms/m2
Deksmedetomidín 500 mikrogramov/m2
MARKETING AUTHORISATION NUMBER(S) EU/2/02/033/003
ŠTEVILKA(E) V DOVOLJENJ(A) ZA PROMET EU/2/02/033/003
The dosage for cats is 40 micrograms dexmedetomidine hydrochloride/kg bw equal to a dose volume 0.08 ml Dexdomitor/kg bw when used for non-invasive, mildly to moderately painful procedures requiring restraint, sedation and analgesia.
Odmerek za mačke je 40 mikrogramov deksmedetomidinijevega klorida/kg telesne teže, kar ustreza prostorninskemu odmerku 0,08 ml Dexdomitorja/kg telesne teže pri uporabi za neinvazivne, blago do zmerno boleče postopke in preglede mačk, pri katerih so potrebni mirovanje, sedacija in analgezija.
One ml contains 0.5 mg dexmedetomidine hydrochloride equivalent to 0.42 mg dexmedetomidine.
1 ml vsebuje 0,5 mg deksmedetomidinijevega klorida, ki ustreza 0,42 mg deksmedetomidina
Dexmedetomidine also induces a number of other α2adrenoceptor mediated effects, which include piloerection, depression of motor and secretory functions of the gastrointestinal tract, diuresis and hyperglycaemia.
Mednje sodijo piloerekcija, upadanje motoričnih in sekretornih funkcij prebavil, diureza in hiperglikemija.
PACKAGE LEAFLET DEXDOMITOR 0.1 mg/ml solution for injection
NAVODILO ZA UPORABO DEXDOMITOR 0,1 mg/ml raztopina za injiciranje
The dosage for cats is 40 micrograms dexmedetomidine hydrochloride/ kg bw equal to a dose volume 0.4 ml Dexdomitor/ kg bw when used for non-invasive, mildly to moderately painful procedures requiring restraint, sedation and analgesia.
Odmerek za mačke je 40 mikrogramov deksmedetomidinijevega klorida/kg telesne teže, kar ustreza prostorninskemu odmerku 0,4 ml Dexdomitorja/kg telesne teže pri uporabi za neinvazivne, blago do zmerno boleče postopke in preglede mačk, pri katerih so potrebni mirovanje, sedacija in analgezija.
0.5 mg dexmedetomidine hydrochloride equivalent to 0.42 mg dexmedetomidine
0,5 mg deksmedetomidinijevega klorida, ki ustreza 0,42 mg deksmedetomidina
PACKAGE LEAFLET DEXDOMITOR 0.5 mg/ml solution for injection
NAVODILO ZA UPORABO DEXDOMITOR 0,5 mg/ml raztopina za injiciranje
When dexmedetomidine is used as a premedicant in dogs bradypnoea, tachypnoea and vomiting may occur.
Pri uporabi deksmedetomidina za pripravo na kirurške posege pri psih lahko pride do bradipneje, tahipneje in bruhanja.
ROUTE(S) OF ADMINISTRATION Dogs: intravenous or intramuscular use Cats: intramuscular use
POT(I) UPORABE ZDRAVILA Psi: intravenska in intramuskularna uporaba Mačke: intramuskularna uporaba
The dose volume of atipamezole at the concentration of 5 mg/ml equals one-half the volume of Dexdomitor that was given to the cat.
Volumen odmerka atipamezola v koncentraciji 5 mg/ml je enak eni polovici volumna odmerka Dexdomitorja, ki je bil dan mački.
0.1 mg dexmedetomidine hydrochloride equivalent to 0.08 mg dexmedetomidine
0,1 mg deksmedetomidinijevega klorida, ki ustreza 0,08 mg deksmedetomidina
DOGS: In cases of overdosage, or if the effects of dexmedetomidine become potentially life-threatening, the appropriate dose of atipamezole is 10 times the initial dose of dexmedetomidine (micrograms/ kg bw or micrograms/ square meter body surface area).
Psi: V primeru prevelikega odmerjanja, ali če postanejo učinki deksmedetomidina potencialno nevarni za življenje, uporabite odmerek atipamezola, 10-krat večji od prvotnega odmerka deksmedetomidina (v mikrogramih/kg telesne teže ali mikrogramih/kvadratni meter telesne površine).
Dogs: In cases of overdosage, or if the effects of dexmedetomidine become potentially life-threatening, the appropriate dose of atipamezole is 10 times the initial dose of dexmedetomidine (micrograms/ kg bw or micrograms/ square meter body surface area).
PSI: V primeru prevelikega odmerjanja, ali če postanejo učinki deksmedetomidina potencialno nevarni za življenje, uporabite odmerek atipamezola, 10-krat večji od prvotnega odmerka deksmedetomidina (v mikrogramih/kg telesne teže ali mikrogramih/kvadratni meter telesne površine).
Methyl parahydroxybenzoate (E 218) 2.0 mg/ml Propyl parahydroxybenzoate (E 216) 0.2 mg/ml
2,0 mg/ml Propilparahidroksibenzoat (E 216) 0,2 mg/ml
Methyl parahydroxybenzoate (E 218) 1.6 mg/ml Propyl parahydroxybenzoate (E 216) 0.2 mg/ml
1,6 mg/ml Propilparahidroksibenzoat (E 216) 0,2 mg/ml
Cats: In cases of overdosage, or if the effects of dexmedetomidine become potentially life-threatening, the appropriate antagonist is atipamezole, administered by intramuscular injection, at the following dose: 5 times the initial dose dexmedetomidine in micrograms/kg bw.
MAČKE: V primeru prevelikega odmerjanja, ali če postanejo učinki deksmedetomidina potencialno nevarni za življenje, uporabite atipamezol v obliki intramuskularne injekcije v naslednjem odmerku: 5-kratni prvotni odmerek deksmedetomidina v mikrogramih/kg telesne teže.
CATS: In cases of overdosage, or if the effects of dexmedetomidine become potentially life-threatening, the appropriate antagonist is atipamezole, administered by intramuscular injection, at the following dose: 5 times the initial dose dexmedetomidine in micrograms/kg bw.
Mačke: V primeru prevelikega odmerjanja, ali če postanejo učinki deksmedetomidina potencialno nevarni za življenje, uporabite atipamezol v obliki intramuskularne injekcije v naslednjem odmerku: 5-kratni prvotni odmerek deksmedetomidina v mikrogramih/kg telesne teže.
WASTE MATERIALS, IF ANY
UPORABE, če je smiselno
METHOD AND ROUTE(S) OF ADMINISTRATION Dogs: intravenous or intramuscular use Cats: intramuscular use
NAČIN IN POT(I) UPORABE Psi: intravenska ali intramuskularna uporaba Mačke: intramuskularna uporaba Pred uporabo preberite navodilo za uporabo.
PHARMACEUTICAL PARTICULARS 6.1 List of excipients Methyl parahydroxybenzoate (E 218) Propyl parahydroxybenzoate (E 216) 6.2 Incompatibilities
Metilparahidroksibenzoat (E 218) Propilparahidroksibenzoat (E 216)
ANNEX 127A CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT TO BE IMPLEMENTED BY THE MEMBER STATES
DODATEK 127A POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA, KI JIH IZVAJAJO DRŽAVE ČLANICE
• Caution in use in the elderly in light of age related risks (in particular bladder cancer, fractures and heart failure).
• Opozorilo o uporabi pri starejših glede na s starostjo povezana tveganja (zlasti za rak mehurja,
Manufacturer - Lilly S.A., Avda.
Izdelovalec • Lilly S.A., Avda.
Date of latest renewal: 8 August 2008
Datum zadnjega podaljšanja dovoljenja za promet: 8. avgust 2008
You should talk to your doctor first.
Predhodno se posvetujte z zdravnikom.
Due to the nature of this disease process, Evista is intended for long term use.
Zaradi narave tega bolezenskega procesa je zdravilo Evista namenjeno dolgotrajni uporabi.
D-81379 Munich Germany
D-81379 Munich Nemčija
Your doctor will tell you how long you should continue to take Evista.
Vaš zdravnik vam bo povedal, kako dolgo naj bi jemali zdravilo Evista.
A similar increase in BMD was seen in the treatment population who received Evista for up to 7 years.
Podobno povečanje BMD so ugotovili pri zdravljeni populaciji, ki je prejemala zdravilo Evista do 7 let.
• Headache including migraine
• Glavobol vključno z migreno
Common: Peripheral oedema
Pogosti: periferni edem
Like all medicines, this medicine can cause side effects although not everybody gets them.
Kot vsa zdravila ima lahko tudi to zdravilo neželene učinke, ki pa se ne pojavijo pri vseh bolnicah.
INFORMATION IN BRAILLE Evista
PODATKI V BRAILLOVI PISAVI Evista
Cholecystectomy rates for raloxifene (2.3 %) were not statistically significantly different from placebo (2.0 %).
Stopnje holecistomije za raloksifen (2,3 %) niso bile statistično značilno drugačne od placeba (2,0 %).
DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION Date of first authorisation: 5 August 1998
DATUM PRIDOBITVE/PODALJŠANJA DOVOLJENJ ZA PROMET Z ZDRAVILOM Datum pridobitve dovoljenja za promet: 5. avgust 1998
If you are taking digitalis medicines for your heart or anticoagulants like warfarin to thin your blood, your doctor may need to adjust your dose of these medicines.
Če jemljete zdravila za srce, ki vsebujejo digitalis, ali antikoagulante za redčenje krvi, kakor je npr. varfarin, vam bo vaš zdravnik morda moral prilagoditi odmerek teh zdravil.
What Evista is and what it is used for
Kaj je zdravilo Evista in za kaj ga uporabljamo
What you need to know before you take Evista
Kaj morate vedeti, preden boste vzeli zdravilo Evista
The following convention has been used for the classification of the adverse reactions: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000).
Za klasifikacijo neželenih učinkov smo uporabili naslednji dogovor: zelo pogosto (≥ 1/10), pogosto (≥ 1/100 do < 1/10), občasno (≥ 1/1.000 do < 1/100), redko (≥ 1/10.000 do < 1/1.000), zelo redko
Evista tablets are packed either in PVC/PE/PCTFE blisters or in high density polyethylene bottles.
Tablete Evista so pakirane v pretisne omote PVC/PE/PCTFE ali v stekleničke iz polietilena visoke gostote.
Any uterine bleeding during Evista therapy is unexpected and should be fully investigated by a specialist.
Vsakršna krvavitev iz maternice med terapijo z zdravilom Evista je nepričakovana in jo mora v celoti raziskati specialist.
Take a tablet as soon as you remember and then continue as before.
Če ste pozabili vzeti zdravilo Evista Vzemite tableto takoj, ko se spomnite, in potem nadaljujte enako kot prej.
The majority of a dose of raloxifene and glucuronide metabolites are excreted within 5 days and are found primarily in the faeces, with less than 6 % excreted in urine.
Večji del odmerka raloksifena in njegovih glukuronidnih presnovkov se izloči v roku 5 dni in jih najdemo predvsem v blatu, manj kot 6 % pa se jih izloči z urinom.
Do not take a double dose to make up for a forgotten tablet dose.
Ne vzemite dvojnega odmerka, če ste pozabili vzeti prejšnji odmerek.
Evista may affect the development of the baby.
Zdravilo Evista lahko vpliva na dojenčkov razvoj.
After 3 years therapy Evista decreased fibrinogen (6.71 %).
Po 3 letih terapije z zdravilom Evista je znižana vrednost fibrinogena (6,71 %).
Evista could harm your unborn child.
Zdravilo Evista lahko poškoduje vašega nerojenega otroka.
Endometrial biopsies taken after six months therapy with Evista 60 mg daily demonstrated nonproliferative endometrium in all patients.
Biopsija endometrija po šestih mesecih terapije z zdravilom Evista v odmerku 60 mg na dan je pri vseh bolnicah pokazala neproliferativni endometrij.
Do not take Evista:
Ne jemljite zdravila Evista:
Effects on prothrombin time may develop over several weeks if Evista treatment is started in patients who are already on coumarin anticoagulant therapy.
Vplivi na protrombinski čas se lahko pokažejo šele čez nekaj tednov, če zdravljenje z zdravilom Evista uvedemo pri bolnicah, ki so že na kumarinski antikoagulantni terapiji.
• If there is still a possibility that you can get pregnant, Evista could harm your unborn child.
• Če je še vedno možnost, da lahko zanosite, saj zdravilo Evista lahko poškoduje vašega nerojenega otroka.
Evista should not be used in patients with signs or symptoms of endometrial cancer as safety in this patient group has not been adequately studied.
Zdravila Evista ne bi smeli uporabljati pri bolnicah, ki kažejo znake ali imajo simptome raka endometrija, saj varnost zdravila pri tej skupini bolnic še ni bila zadosti raziskana.
Data suggests that the oestrogen receptor can regulate gene expression by at least two distinct pathways which are ligand-, tissue-, and/or genespecific.
Podatki kažejo, da lahko estrogenski receptor regulira gensko ekspresijo po vsaj dveh različnih poteh, ki sta specifični za ligand, tkivo in/ali gen.
Raloxifene has no or negligible influence on the ability to drive and use machines.
Raloksifen nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
Evista was associated with reduced bone resorption and a mean positive shift in calcium balance of 60 mg per day, due primarily to decreased urinary calcium losses.
Uporaba zdravila Evista je bila povezana z zmanjšano resorpcijo kostnega tkiva in s srednjim pozitivnim premikom ravnotežja kalcija za 60 mg na dan, kar je bilo predvsem posledica zmanjšane izgube kalcija z urinom.
It is important that you continue taking Evista for as long as your doctor prescribes the medicine.
Pomembno je, da nadaljujete z jemanjem zdravila Evista toliko časa kot vam je predpisal vaš zdravnik.
From the 4th to the 8th year, patients were permitted the concomitant use of bisphosphonates, calcitonin and fluorides and all patients in this study received calcium and vitamin D supplementation.
Od četrtega do osmega leta zdravljenja so bolnicam dovolili sočasno jemanje difosfonatov, kalcitonina in fluoridov in vse bolnice iz te raziskave so jemale dodatke kalcija in vitamina D.
ii) Bone Mineral Density (BMD): The efficacy of Evista once daily in postmenopausal women aged up to 60 years and with or without a uterus was established over a two-year treatment period.
ii) Mineralna kostna gostota (BMD): Učinkovitost zdravljenja z zdravilom Evista enkrat dnevno so ugotavljali pri ženskah po menopavzi, starih do 60 let, z maternico ali brez nje, in sicer med 2-letnim zdravljenjem s tem zdravilom.
If you have been told by your doctor that you have an intolerance to lactose, a type of sugar, contact your doctor before taking this medicinal product.
Če vam je zdravnik povedal, da ne prenašate laktoze, ki je vrsta sladkorja, se pred uporabo tega zdravila posvetujte z zdravnikom.
Evista is for use only by postmenopausal women and must not be taken by women who could still have a baby.
Zdravilo Evista je namenjeno le ženskam po menopavzi in je ne smejo jemati ženske, ki bi še lahko zanosile.
Clinical trials showed that a 60 mg daily dose of Evista significantly decreased total cholesterol (3 to 6 %), and LDL cholesterol (4 to 10 %).
Klinične raziskave so pokazala, da dnevni odmerek zdravila Evista 60 mg značilno zniža vrednosti skupnega holesterola (3 do 6 %) in LDL holesterola (4 do 10 %).
Other medicines and Evista
Druga zdravila in zdravilo Evista
However, if you have taken oestrogen in the past and had extreme elevations in triglycerides, you should talk to your doctor before taking Evista.
Če ste v preteklosti že jemali estrogene in ob tem imeli močno zvišane vrednosti trigliceridov, se pred jemanjem zdravila Evista pogovorite z zdravnikom.
Evista is not effective in reducing vasodilatation (hot flushes), or other symptoms of the menopause associated with oestrogen deficiency.
Evista ni učinkovito zdravilo za zmanjševanje vazodilatacije (navalov vročine) ali drugih simptomov menopavze, ki so povezani s pomanjkanjem estrogena.
In addition, in a study with 2.5 x the recommended daily dose of Evista there was no evidence of endometrial proliferation and no increase in uterine volume.
Poleg tega v raziskavi z 2,5-kratnim priporočenim dnevnim odmerkom zdravila Evista ni bilo nobenih znakov proliferacije endometrija in niso ugotovili povečanja prostornine maternice.
Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
Obvestite zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katero koli drugo zdravilo.
b) Effects on lipid metabolism and cardiovascular risk
b) Vplivi na presnovo lipidov in srčnožilno tveganje
Tell your doctor if you are taking cholestyramine which is mainly used as lipid-lowering medicine, because Evista may not work as well.
Obvestite svojega zdravnika, če jemljete holestiramin, ki se uporablja predvsem kot zdravilo za zniževanje koncentracij lipidov v krvi, saj zdravilo Evista v tem primeru morda ne bo delovalo dovolj dobro.